172 related articles for article (PubMed ID: 23336246)
1. Treatment patterns and therapy effectiveness in psoriasis patients initiating biologic therapy in England.
Khalid JM; Fox KM; Globe G; Maguire A; Chau D
J Dermatolog Treat; 2014 Feb; 25(1):67-72. PubMed ID: 23336246
[TBL] [Abstract][Full Text] [Related]
2. Durable dermatology life quality index improvements in patients on biologics associated with psoriasis areas and severity index: a longitudinal study.
Chaptini C; Quinn S; Marshman G
Australas J Dermatol; 2016 Aug; 57(3):e72-5. PubMed ID: 26010650
[TBL] [Abstract][Full Text] [Related]
3. Psoriasis Area Severity Index (PASI) and the Dermatology Life Quality Index (DLQI): the correlation between disease severity and psychological burden in patients treated with biological therapies.
Mattei PL; Corey KC; Kimball AB
J Eur Acad Dermatol Venereol; 2014 Mar; 28(3):333-7. PubMed ID: 23425140
[TBL] [Abstract][Full Text] [Related]
4. The effect of weight reduction on treatment outcomes in obese patients with psoriasis on biologic therapy: a randomized controlled prospective trial.
Al-Mutairi N; Nour T
Expert Opin Biol Ther; 2014 Jun; 14(6):749-56. PubMed ID: 24661040
[TBL] [Abstract][Full Text] [Related]
5. Blood Monocyte Count Can Predict Early Response to Secukinumab Therapy in Patients With Psoriasis.
Ziolkowska-Banasik D; Hadas E; Pastuszczak M
J Drugs Dermatol; 2024 Feb; 23(2):74-77. PubMed ID: 38306130
[TBL] [Abstract][Full Text] [Related]
6. Physician Global Assessment (PGA) and Psoriasis Area and Severity Index (PASI): why do both? A systematic analysis of randomized controlled trials of biologic agents for moderate to severe plaque psoriasis.
Robinson A; Kardos M; Kimball AB
J Am Acad Dermatol; 2012 Mar; 66(3):369-75. PubMed ID: 22041254
[TBL] [Abstract][Full Text] [Related]
7. Efficacy and safety of etanercept in psoriasis after switching from other treatments: an observational study.
Mazzotta A; Esposito M; Costanzo A; Chimenti S
Am J Clin Dermatol; 2009; 10(5):319-24. PubMed ID: 19658444
[TBL] [Abstract][Full Text] [Related]
8. Cost effectiveness of biologic therapies for plaque psoriasis.
Ahn CS; Gustafson CJ; Sandoval LF; Davis SA; Feldman SR
Am J Clin Dermatol; 2013 Aug; 14(4):315-26. PubMed ID: 23696234
[TBL] [Abstract][Full Text] [Related]
9. Investigation of the efficacy of Dr Michaels® (Soratinex®) family in maintaining a symptom-free state for patients with psoriasis in remission. A retrospective, comparative study.
Hercogovấ J; Fioranelli M; Gianfaldoni S; Chokoeva AA; Tchernev G; Wollina U; Tirant M; Novotny F; Roccia MG; Maximov GK; França K; Lotti T
J Biol Regul Homeost Agents; 2016; 30(2 Suppl 3):73-5. PubMed ID: 27498661
[TBL] [Abstract][Full Text] [Related]
10. Review of the reasons for and effectiveness of switching biologics for psoriasis treatment in Korea.
Shin JO; Shin BS; Bae KN; Shin K; Kim HS; Ko HC; Kim MB; Kim B
Indian J Dermatol Venereol Leprol; 2023; 89(6):928. PubMed ID: 37317715
[TBL] [Abstract][Full Text] [Related]
11. [Clinical experience with etanercept in the treatment of psoriasis].
Martín B; Sánchez-Carazo JL; Pérez-Ferriols A; Laguna C; Oliver V; Alegre V
Actas Dermosifiliogr; 2008 Sep; 99(7):540-5. PubMed ID: 18682167
[TBL] [Abstract][Full Text] [Related]
12. Efficacy of adalimumab in the treatment of moderate-to-severe psoriasis: A retrospective study of 100 patients in daily practice.
Armesto S; Coto-Segura P; Mayorga J; Illaro A; Santos-Juanes J
J Dermatolog Treat; 2015 Feb; 26(1):49-53. PubMed ID: 24552591
[TBL] [Abstract][Full Text] [Related]
13. Standardizing training for psoriasis measures: effectiveness of an online training video on Psoriasis Area and Severity Index assessment by physician and patient raters.
Armstrong AW; Parsi K; Schupp CW; Mease PJ; Duffin KC
JAMA Dermatol; 2013 May; 149(5):577-82. PubMed ID: 23426158
[TBL] [Abstract][Full Text] [Related]
14. Decision for biological treatment in real life is more strongly associated with the Psoriasis Area and Severity Index (PASI) than with the Dermatology Life Quality Index (DLQI).
Hägg D; Sundström A; Eriksson M; Schmitt-Egenolf M
J Eur Acad Dermatol Venereol; 2015 Mar; 29(3):452-6. PubMed ID: 24911993
[TBL] [Abstract][Full Text] [Related]
15. Myocardial function and effects of biologic therapy in patients with severe psoriasis: a prospective echocardiographic study.
Ahlehoff O; Hansen PR; Gislason GH; Frydland M; Bryld LE; Elming H; Jemec GB
J Eur Acad Dermatol Venereol; 2016 May; 30(5):819-23. PubMed ID: 25845841
[TBL] [Abstract][Full Text] [Related]
16. Switching from etanercept to adalimumab is effective and safe: results in 30 patients with psoriasis with primary failure, secondary failure or intolerance to etanercept.
Van Lümig PP; Lecluse LL; Driessen RJ; Spuls PI; Boezeman JB; van de Kerkhof PC; De Jong EM
Br J Dermatol; 2010 Oct; 163(4):838-46. PubMed ID: 20649798
[TBL] [Abstract][Full Text] [Related]
17. Patient-reported outcomes are important elements of psoriasis treatment decision making: A discrete choice experiment survey of dermatologists in the United States.
Feldman SR; Regnier SA; Chirilov A; Hey F; Gilloteau I; Cella D
J Am Acad Dermatol; 2019 Jun; 80(6):1650-1657. PubMed ID: 30703461
[TBL] [Abstract][Full Text] [Related]
18. Superiority in Quality of Life Improvement of Biologics over Conventional Systemic Drugs in a Swiss Real-Life Psoriasis Registry.
Jungo P; Maul JT; Djamei V; von Felten S; Kolios AGA; Czernielewsk J; Yawalkar N; Odermatt O; Laffitte E; Anliker M; Streit M; Augustin M; Conrad C; Hafner J; Boehncke WH; Gilliet M; Itin P; French LE; Navarini AA; Häusermann P
Dermatology; 2016; 232(6):655-663. PubMed ID: 28103601
[TBL] [Abstract][Full Text] [Related]
19. Successful adalimumab treatment of a psoriasis vulgaris patient with hemodialysis for renal failure: A case report and a review of the previous reports on biologic treatments for psoriasis patients with hemodialysis for renal failure.
Kusakari Y; Yamasaki K; Takahashi T; Tsuchiyama K; Shimada-Omori R; Nasu-Tamabuchi M; Aiba S
J Dermatol; 2015 Jul; 42(7):727-30. PubMed ID: 25916786
[TBL] [Abstract][Full Text] [Related]
20. Rethinking the Psoriasis Area and Severity Index: the impact of area should be increased.
Jacobson CC; Kimball AB
Br J Dermatol; 2004 Aug; 151(2):381-7. PubMed ID: 15327545
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
